A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Belinostat in Patients With Advanced Cancer

Trial Profile

A Phase 1 Study for the Evaluation of Excretion (Mass Balance) and Pharmacokinetics of 14C-Labeled Belinostat in Patients With Advanced Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Belinostat (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 14 Jan 2016 Status changed from active, no longer recruiting to completed, as per an article published in the Investigational New Drugs
    • 14 Jan 2016 Results published in the Investigational New Drugs
    • 10 Mar 2015 Planned End Date changed from 1 Apr 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top